Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRT-R912 + GRT-R914 + GRT-R918
- Development stage
- Unknown
- Lead developer
- Gritstone Oncology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
GRT-R912 + GRT-R914 + GRT-R918 is a combination of second-generation self-amplifying mRNA (samRNA) vaccine candidates developed by Gritstone bio for the prevention of COVID-19. These vaccines utilize a codon-optimized Spike cassette along with additional T cell epitopes (TCE) derived from highly conserved non-spike proteins (Nucleocapsid, Membrane, ORF3a, and Non-structural Proteins) to elicit broad and durable B cell and T cell immune responses. GRT-R912 and GRT-R914 target the Beta variant spike, while GRT-R918 targets the Omicron variant spike. The samRNA platform is designed to provide higher and more sustained protein expression at lower doses compared to conventional mRNA vaccines. The combination is currently being evaluated in the Phase 1 CORAL-CEPI clinical trial.
- Other names
- CORAL-CEPI vaccine
02
Targets
SARS-CoV-2 Membrane protein-derived T-cell epitopesN (Nucleocapsid protein)SARS-CoV-2 open reading frame 3a-derived T-cell epitopesSARS-CoV-2 spikeORF3a (SARS-CoV-2 ORF3a protein)M protein (SARS-CoV-2 membrane protein)pp1a (Replicase polyprotein 1a)
Beyond the preview
Go deeper on GRT-R912 + GRT-R914 + GRT-R918.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRT-R912 + GRT-R914 + GRT-R918.